ReviewCancer biotherapy & radiopharmaceuticals2020
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.
Review in Cancer biotherapy & radiopharmaceuticals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026Review
- Targeted Alpha Therapy as a Multiscale Design Problem: From Radioactive Decay to Therapeutic Outcome.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.Molecular cancer · 2026Review
- Inhibiting NHEJ: In-Silico Approach to Stratifying DNA-PK Inhibitors, Predicting Radio-Halogenation Potential of DNA-PK Inhibitors, and Assessing AlphaFold2 Prediction Accuracy.Bioengineering (Basel, Switzerland) · 2026Article
- Solving the limited availability of Astatine-211 from a European perspective: from production to the end user.EJNMMI radiopharmacy and chemistry · 2026Review
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Editorial: Radiolabeled Peptides in Cancer Imaging and Therapy-Emerging Isotopes.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Feasibility of targeted alpha therapy for Alzheimer's disease usingAnnals of nuclear medicine · 2025Article
- Ortho-functionalization of aScientific reports · 2025Article
- Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment.Theranostics · 2025Review
- Novel astatine (European journal of nuclear medicine and molecular imaging · 2025Article
- Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI radiopharmacy and chemistry · 2024Review
- Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (European journal of nuclear medicine and molecular imaging · 2024Article
- Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.Theranostics · 2024Review
- Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future.Current radiopharmaceuticals · 2024Review
- Radiochemistry: A Hot Field with Opportunities for Cool Chemistry.ACS central science · 2023Review
- Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Therapeutic efficacy ofChemical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-211 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.